Samantha C Erosa1, Paul R Haffey2, Neel Mehta3, Amitabh Gulati4. 1. Department of Rehabilitation and Regenerative Medicine, NewYork-Presbyterian, The University Hospital of Columbia and Cornell, New York, NY, USA. sae9043@nyp.org. 2. Department of Anesthesiology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, USA. 3. Division of Pain Medicine, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, USA. 4. Department of Anesthesia and Critical Care, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, USA.
Abstract
PURPOSE OF REVIEW: The objective of this systematic review is to present the available evidence for the utilization of the atypical opioids tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain. RECENT FINDINGS: In total, 1619 articles were retrieved of which 10 studies were included. Of 5 included studies pertaining to tapentadol, 4 studies show tapentadol monotherapy to be effective for the treatment of diabetic peripheral neuropathy or chronic, radiating low back pain. Of the 3 studies included for buprenorphine, only one was a randomized controlled trial found not to have a statistically significant reduction in pain with TD buprenorphine likely due to very high withdrawal rates during the trial. Only 2 case reports were included from the available literature for levorphanol providing low-quality anecdotal evidence. The role of tapentadol, buprenorphine, and levorphanol for neuropathic pain conditions requires robust research including randomized controlled trials to evaluate their efficacy and safety.
PURPOSE OF REVIEW: The objective of this systematic review is to present the available evidence for the utilization of the atypical opioids tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain. RECENT FINDINGS: In total, 1619 articles were retrieved of which 10 studies were included. Of 5 included studies pertaining to tapentadol, 4 studies show tapentadol monotherapy to be effective for the treatment of diabetic peripheral neuropathy or chronic, radiating low back pain. Of the 3 studies included for buprenorphine, only one was a randomized controlled trial found not to have a statistically significant reduction in pain with TD buprenorphine likely due to very high withdrawal rates during the trial. Only 2 case reports were included from the available literature for levorphanol providing low-quality anecdotal evidence. The role of tapentadol, buprenorphine, and levorphanol for neuropathic pain conditions requires robust research including randomized controlled trials to evaluate their efficacy and safety.
Authors: Rudolf Martin Duehmke; Sheena Derry; Philip J Wiffen; Rae F Bell; Dominic Aldington; R Andrew Moore Journal: Cochrane Database Syst Rev Date: 2017-06-15
Authors: Richard C Dart; Theodore J Cicero; Hilary L Surratt; Andrew Rosenblum; Becki Bucher Bartelson; Edgar H Adams Journal: J Opioid Manag Date: 2012 Nov-Dec
Authors: Karen Miotto; Arthur K Cho; Mohamed A Khalil; Kirsten Blanco; Jun D Sasaki; Richard Rawson Journal: Anesth Analg Date: 2017-01 Impact factor: 5.108
Authors: Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace Journal: Lancet Neurol Date: 2015-01-07 Impact factor: 44.182
Authors: Anna Dziubina; Anna Rapacz; Anna Czopek; Małgorzata Góra; Jolanta Obniska; Krzysztof Kamiński Journal: Int J Mol Sci Date: 2022-04-06 Impact factor: 5.923
Authors: Cornelius Fernandez James; Shiva Tripathi; Kyriaki Karampatou; Divya V Gladston; Joseph M Pappachan Journal: Sisli Etfal Hastan Tip Bul Date: 2022-03-28